How can we help?
d) a and b
Kidney transplant can come from which of the following?
a) living related
b) cadaver
c) positive blood match
d) a and b
e) a and c
a) living related
b) cadaver
c) positive blood match
d) a and b
e) a and c
c) patient has been in cancer remission for 24 months
A recipient can be denied a kidney transplant for all of the following EXCEPT:
a) non adherence to treatment regime
b) psycho-emotional stability
c) patient has been in cancer remission for 24 months
d) patient lacks adequate bladder capacity
e) a patient can be denied a transplant for all of the above
a) non adherence to treatment regime
b) psycho-emotional stability
c) patient has been in cancer remission for 24 months
d) patient lacks adequate bladder capacity
e) a patient can be denied a transplant for all of the above
T
The failed kidney(s) are left in place.
T/F
T/F
Abdomen, aorta, inferior vena cava
Small children receiving large kidneys will have it placed in the ___________ with circulation attached to the ___________ and _____________.
b. twin
a. sibling from same parents
d. parent
c. grandparent
e. unrelated donor
a. sibling from same parents
d. parent
c. grandparent
e. unrelated donor
List donors in order from best to poorest match:
a. sibling from same parents
b. twin
c. grandparent
d. parent
e. unrelated donor
a. sibling from same parents
b. twin
c. grandparent
d. parent
e. unrelated donor
d. a and b
Goal of immunotherapy in organ transplant is to:
a. minimize rejection
b. maintain adequate infection control response
c. manage an autoimmune disorder
d. a and b
e. b and c
a. minimize rejection
b. maintain adequate infection control response
c. manage an autoimmune disorder
d. a and b
e. b and c
T
Rejection is the process by which a new kidney is recognized as not "self". The body responds similarly to an infection and seeks to destroy the "invader.
T/F
T/F
T
Immunotherapy makes a patient more susceptible to infection.
T/F
T/F
c. H2 inhibitor
Immunosuppressant drugs include all of the following EXCEPT:
a. Cyclosporin A (CSA)
b. Prednisone
c. H2 inhibitor
d. Mycophenolate
e. Prograf
a. Cyclosporin A (CSA)
b. Prednisone
c. H2 inhibitor
d. Mycophenolate
e. Prograf
T cell
Cyclosporin A (CSA) and Prograf reduces _________ activity
e. all of the above
Mycophenolate decreases production of:
a. Antibodies
b. cytotoxic T cells
c. B cells
d. a and c
e. all of the above
a. Antibodies
b. cytotoxic T cells
c. B cells
d. a and c
e. all of the above
d. mast cells
Prednisone suppresses all of the following immune activities EXCEPT:
a. B cells
b. T cells
c. WBC's
d. mast cells
e. none of the above
a. B cells
b. T cells
c. WBC's
d. mast cells
e. none of the above
d. antiseptic
Secondary prophylactic med(s) include all of the following EXCEPT:
a. antifungal
b. antibacterial
c. antiviral
d. antiseptic
e. H2 inhibitor
a. antifungal
b. antibacterial
c. antiviral
d. antiseptic
e. H2 inhibitor
a. Nystatin and fluconozole
Common anti-fungal med(s) prescribed for secondary prophylaxis include the following:
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. a and d
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. a and d
b. Septra and dapsone
Common anti-bacterial med(s) prescribed for secondary prophylaxis include all of the following:
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. b and d
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. b and d
c. Acyclovir and gangcyclovir
Common anti-viral med(s) prescribed for secondary prophylaxis include all of the following:
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. c and d
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. c and d
d. Ranitidine
Common H2 inhibitor med(s) prescribed for secondary prophylaxis include all of the following:
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. none of the above
a. Nystatin and fluconozole
b. Septra and dapsone
c. Acyclovir and gangcyclovir
d. Ranitidine
e. none of the above
c. Prednisone
H2 inhibitors are prescribed to counteract the side-effects of which drug(s)?
a. cyclosporine
b. mycophenolate
c. Prednisone
d. Nystatin and fluconozole
e. b and c
a. cyclosporine
b. mycophenolate
c. Prednisone
d. Nystatin and fluconozole
e. b and c
c. biopsy
What can definitively determine if acute rejection is occurring?
a. diminished urinary output
b. increased BUN and Cr
c. biopsy
d. a and b
e. b and c
a. diminished urinary output
b. increased BUN and Cr
c. biopsy
d. a and b
e. b and c
b. increased urinary output
Signs and symptoms of acute rejection in a kidney transplant includes all of the following EXCEPT:
a. fever
b. increased urinary output
c. swelling and tenderness over graft site
d. hypertension
e. increased BUN and Cr
a. fever
b. increased urinary output
c. swelling and tenderness over graft site
d. hypertension
e. increased BUN and Cr
3, IV
Mild acute rejection involves ____ day(s) of pulse steroids (methylprednisolone) by what route ____?
Antilymphocytic globulin (ATG)
What drug is given for moderate acute rejection?
monoclonal antibodies (OKT3)
What drug is given for severe acute rejection?
T
Many children by age 5 will have had 2-3 kidney transplants.
T/F
T/F
b. They face greater problems with adherence to drug regime
Adolescents have the greatest rejection rate because
a. Their immune systems are less responsive to immunotherapy
b. They face greater problems with adherence to drug regime
c. They are more susceptible to secondary infections
d. a and b
e. a and c
a. Their immune systems are less responsive to immunotherapy
b. They face greater problems with adherence to drug regime
c. They are more susceptible to secondary infections
d. a and b
e. a and c
a. a patient with a history of UTI
Key predictors for kidney grafting prognosis include all of the following EXCEPT:
a. a patient with a history of UTI
b. a patient currently receiving dialysis
c. the patient's age
d. the race of the patient
e. whether the patient experienced early acute rejection
a. a patient with a history of UTI
b. a patient currently receiving dialysis
c. the patient's age
d. the race of the patient
e. whether the patient experienced early acute rejection
T
The kidney graft survival rate for a 3 y.o. patient is 72%.
T/F
T/F
T
The kidney graft survival rate for a 1 y.o. patient is 81%.
T/F
T/F
a. internal iliac artery and hypogastric vein
The renal artery is anastamosed to the:
a. internal iliac artery and hypogastric vein
b. aorta
c. inferior vena cava and aorta
d. femoral artery
e. b and d
a. internal iliac artery and hypogastric vein
b. aorta
c. inferior vena cava and aorta
d. femoral artery
e. b and d